

Allergic Reactions and Sudden Death With Asenapine

To the Editor: The recent review of the antipsychotic asenapine¹ omitted recent US Food and Drug Administration warnings about allergic reactions and sudden death with this product.^{2,3} I think that there should be a note about this risk in an upcoming edition of this journal with a case example for discussion. For some patients and physicians, knowing this risk might be a relative contraindication for its use. Please consider doing this.

REFERENCES

1. Potkin SG. Asenapine: a clinical overview. *J Clin Psychiatry*. 2011;72(suppl 1):14–18.
2. Cassels C. Atypical antipsychotic linked to life-threatening reactions. <http://www.medscape.com/viewarticle/748960>. Published September 1, 2011. Accessed January 28, 2012.
3. US Food and Drug Administration. Saphris (asenapine maleate): Drug Safety Communication: Serious Allergic Reactions. Published September 1, 2011. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm270600.htm?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=asenapine&utm_content=2. Accessibility verified April 10, 2012.

Kim J. Masters, MD
kimjmasters@brontosaur.org

Author affiliation: Three Rivers Residential Treatment Center, Midlands Campus, West Columbia, South Carolina.

Potential conflicts of interest: None reported.

Funding/support: None reported.

doi:10.4088/JCP.12lr07678

© Copyright 2012 Physicians Postgraduate Press, Inc.